Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

European Journal of Heart Failure

Volumn 12, Issue 9, 2010, Pages 903-912

  Gómez Garre, Dulcenombre ^a   González Rubio, Ma Luisa ^a   González Rubio, M Luisa ^a   Muñoz Pacheco, Paloma ^a   Caro Vadillo, Alicia ^b   Aragoncillo, Paloma ^a   Fernández Cruz, Arturo ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Cardiac remodelling; Inflammation; Preserved systolic function heart failure; Statins

Indexed keywords

CARVEDILOL; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; QUINAPRIL; ROSUVASTATIN; TORASEMIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDITIS; CONTROLLED STUDY; DRUG EFFECT; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; LIPID BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; SYSTOLIC BLOOD PRESSURE;

ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FLUOROBENZENES; FOLLOW-UP STUDIES; HEART FAILURE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PILOT PROJECTS; PYRIMIDINES; RATS; RATS, INBRED SHR; STROKE VOLUME; SULFONAMIDES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 77955971998     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfq101     Document Type: Article

References (31)

1. Lalande S, Johnson BD. Diastolic dysfunction: a link between hypertension and heart failure. Drugs Today (Barc) 2008;44:503-513.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, Van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
3. Clemenson ND, Ebrahim S, Smith GD, LaRosa JC. Statin and risk of coronary heart disease. J Am Med Assoc 2000;283:2935-2936.
4. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642-648.
5. Tsouli SG, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS. Should a statin be prescribed to every patient with heart failure? Heart Fail Rev 2008;13: 211-225.
6. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, Van Veldhuisen DJ, Waagstein F, Wedel H, Wikstr J, CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261.
7. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosu-vastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239.
8. Fukuta H, Little WC. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin 2008;4:209-216.
9. Jasińska M, Owczarek J, Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007; 59:483-499.
10. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyo-pathy. J Am Coll Cardiol 2008;51:415-426.
11. Heyen JR, Blasi ER, Nikula K, Rocha R, Daust HA, Frierdich G, Van Vleet JF, De Ciechi P, McMahon EG, Rudolph AE. Structural, functional, and molecular characterization of the SHHF model of heart failure. Am J Physiol Heart Circ Physiol 2002; 283:H1775-H1784.
12. Gómez-Garre D, Herraiz M, González-Rubio ML, Bernal R, Aragoncillo P, Carbonell A, Rufilanchas JJ, Fernández-Cruz A. Activation of peroxisome proliferator-activated receptor-a and-g in auricular tissue from patients with human failing heart due to ischemic cardiomyopathy. Eur J Heart Fail 2006;8: 154-161.
13. Mangat S, Agarwal S, Rosendorff C. Do statins lower blood pressure? J Cardiovasc Pharmacol Ther 2007;12:112-123.
14. Gross V, Schneider W, Schunck WH, Mervaala E, Luft FC. Chronic effects of lovastatin and bezafibrate on cortical and medullary hemodynamics in deoxycor-ticosterone acetate-salt hypertensive mice. J Am Soc Nephrol 1999;10:1430-1439.
15. Dechend R, Müller D, Park JK, Fiebeler A, Haller H, Luft FC. Statins and angioten-sin II-induced vascular injury. Nephrol Dial Transplant 2002;17:349-353.
16. Susic D, Varagic J, Ahn J, Slama M, Frohlich ED. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. J Am Coll Cardiol 2003;42: 1091-1097.
17. Loch D, Levick S, Hoey A, Brown L. Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. J Cardiovasc Pharmacol 2006;47:396-404.
18. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Nishizawa T, Noda A, Izawa H, Nagata K, Murohara T, Yokota M. Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006;47: 770-779.
19. Tsotetsi OJ, Woodiwiss AJ, Netjhardt M, Qubu D, Brooksbank R, Norton GR. Attenuation of cardiac failure, dilatation, damage, and detrimental interstitial remodeling without regression of hypertrophy in hypertensive rats. Hypertension 2001;38:846-851.
20. Sironi L, Gianazza E, Gelosa P, Guerrini U, Nobili E, Gianella A, Cremonesi B, Paoletti R, Tremoli E. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol 2005;25:598-603.
21. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, Bellosta S, Canavesi M, Rottoli D, Guerrini U, Brioschi M, Banfi C, Tremoli E, Remuzzi G, Sironi L. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007;170:1165-1177.
22. Suh JW, Choi DJ, Chang HJ, Cho YS, Youn TJ, Chae IH, Kim KI, Kim CH, Kim HS, Oh BH, Park YB. HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. J Korean Med Sci 2010;25:16-23.
23. Aukrust P, Ueland T, Müller F, Andreassen AK, Nordøy I, Aas H, Kjekshus J, Simonsen S, Frøland SS, Gullestad L. Elevated circulating levels of C-C chemo-kines in patients with congestive heart failure. Circulation 1998;97:1136-1143.
24. Niu J, Kolattukudy PE. Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 2009;117:95-109.
25. Sicard P, Delemasure S, Korandji C, Segueira-Le Grand A, Lauzier B, Guilland JC, Duvillard L, Zeller M, Cottin Y, Vergely C, Rochette L. Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats. Free Radic Res 2008;42:226-236.
26. Gilmore TD. Introduction to NF-kB: players, pathways, perspectives. Oncogene 2006;25:6680-6684.
27. Robinson E, Grieve DJ. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther 2009; 122:246-263.
28. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792-2800.
29. López B, Querejeta R, González A, Sánchez E, Larman M, Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-2035.
30. Gómez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, López-Armada MJ, Plaza JJ, González E, Egido J. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885-892.
31. Sugden PH. Signaling pathways activated by vasoactive peptides in the cardiac myocyte and their role in myocardial pathologies. J Card Fail 2002;8:S359-S369.